Pierre-Emmanuel Brachet

676 total citations
18 papers, 118 citations indexed

About

Pierre-Emmanuel Brachet is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Pierre-Emmanuel Brachet has authored 18 papers receiving a total of 118 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Surgery. Recurrent topics in Pierre-Emmanuel Brachet's work include Renal cell carcinoma treatment (4 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Pierre-Emmanuel Brachet is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Pierre-Emmanuel Brachet collaborates with scholars based in France, Italy and Luxembourg. Pierre-Emmanuel Brachet's co-authors include Florence Joly, Fabien Tinquaut, Domenica Lorusso, Véronique D’Hondt, Frédérique Rousseau, Olivier Trédan, Mélanie Dos Santos, Claire Falandry, Bénédicte Clarisse and Gilles Freyer and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancer Treatment Reviews.

In The Last Decade

Pierre-Emmanuel Brachet

15 papers receiving 118 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre-Emmanuel Brachet France 6 47 39 35 32 17 18 118
Birutė Brasiūnienė Lithuania 8 71 1.5× 38 1.0× 17 0.5× 25 0.8× 23 1.4× 27 126
Annick Chevalier-Place France 6 56 1.2× 48 1.2× 61 1.7× 27 0.8× 33 1.9× 7 148
Giorgia Trevisan United Kingdom 7 54 1.1× 24 0.6× 55 1.6× 44 1.4× 25 1.5× 11 143
Nadia Raban France 7 62 1.3× 21 0.5× 47 1.3× 23 0.7× 43 2.5× 17 145
Н. В. Коваленко Russia 8 84 1.8× 25 0.6× 48 1.4× 25 0.8× 28 1.6× 25 167
Bruno Chiurazzi Italy 5 50 1.1× 24 0.6× 35 1.0× 23 0.7× 31 1.8× 12 118
Chu Van Nguyen Vietnam 7 62 1.3× 37 0.9× 9 0.3× 11 0.3× 20 1.2× 36 114
Petra Jankowska United Kingdom 4 34 0.7× 24 0.6× 21 0.6× 31 1.0× 35 2.1× 6 141
Hanmei Lou China 6 96 2.0× 28 0.7× 16 0.5× 32 1.0× 19 1.1× 14 154
Carlijn van de Water Netherlands 6 69 1.5× 43 1.1× 5 0.1× 39 1.2× 24 1.4× 11 144

Countries citing papers authored by Pierre-Emmanuel Brachet

Since Specialization
Citations

This map shows the geographic impact of Pierre-Emmanuel Brachet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre-Emmanuel Brachet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre-Emmanuel Brachet more than expected).

Fields of papers citing papers by Pierre-Emmanuel Brachet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre-Emmanuel Brachet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre-Emmanuel Brachet. The network helps show where Pierre-Emmanuel Brachet may publish in the future.

Co-authorship network of co-authors of Pierre-Emmanuel Brachet

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre-Emmanuel Brachet. A scholar is included among the top collaborators of Pierre-Emmanuel Brachet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre-Emmanuel Brachet. Pierre-Emmanuel Brachet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Coquan, Elodie, Nicolas Penel, Raphaël Leman, et al.. (2024). Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial. Therapeutic Advances in Urology. 16. 3643576372–3643576372.
2.
Stefan, Dinu, Justine Lequesne, Delphine Larrieu‐Ciron, et al.. (2023). Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.. Journal of Clinical Oncology. 41(16_suppl). 2046–2046. 1 indexed citations
3.
Coquan, Elodie, Justine Lequesne, Émeline Colomba, et al.. (2022). 2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study). International Journal of Gynecological Cancer. 32. A14–A14.
4.
Falandry, Claire, Fanny Pommeret, Laurence Gladieff, et al.. (2022). Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. The Lancet Healthy Longevity. 3(3). e176–e185. 7 indexed citations
5.
Santos, Mélanie Dos, Justine Lequesne, Alexandra Leconte, et al.. (2022). Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). BMC Cancer. 22(1). 537–537. 17 indexed citations
6.
7.
Elie, Nicolas, Florence Giffard, Cécile Blanc‐Fournier, et al.. (2022). Impact of automated methods for quantitative evaluation of immunostaining: Towards digital pathology. Frontiers in Oncology. 12. 931035–931035. 4 indexed citations
8.
Coquan, Elodie, Pierre-Emmanuel Brachet, Isabelle Bonnet, et al.. (2022). Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations. Current Oncology. 29(4). 2776–2791. 2 indexed citations
9.
Coquan, Elodie, Pierre-Emmanuel Brachet, Idlir Licaj, et al.. (2021). CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure. BMC Cancer. 21(1). 1054–1054. 3 indexed citations
10.
Falandry, Claire, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier, et al.. (2021). Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer. JAMA Oncology. 7(6). 853–853. 46 indexed citations
11.
12.
Lesueur, Paul, Alexandra Leconte, Julien Geffrelot, et al.. (2020). Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial. BMC Cancer. 20(1). 147–147. 7 indexed citations
13.
14.
Tinquaut, Fabien, Gilles Freyer, Fanny Pommeret, et al.. (2019). Validation of the geriatric vulnerability score (GVS) in older ovarian cancer (oOC) patients: An analysis from the GCIG-ENGOT-GINECO EWOC-1 study. Annals of Oncology. 30. v406–v407.
15.
Brachet, Pierre-Emmanuel, Michel Fabbro, Alexandra Léary, et al.. (2017). A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC). Annals of Oncology. 28. v347–v347. 4 indexed citations
16.
Johnson, Alison, Margarida Matias, Helen Boyle, et al.. (2017). Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. BMC Cancer. 17(1). 355–355. 5 indexed citations
17.
Santos, Mélanie Dos, Pierre-Emmanuel Brachet, Christine Chevreau, & Florence Joly. (2016). Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit. Cancer Treatment Reviews. 53. 53–60. 9 indexed citations
18.
Johnson, Alison, Margarida Matias, Elodie Coquan, et al.. (2016). Prognostic value of hemoglobin level increase during axitinib treatment for metastatic renal cell carcinoma.. Journal of Clinical Oncology. 34(2_suppl). 580–580. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Birutė Brasiūnienė Breakdown of academic impact, for papers by Annick Chevalier-Place Breakdown of academic impact, for papers by Giorgia Trevisan Breakdown of academic impact, for papers by Nadia Raban Breakdown of academic impact, for papers by Н. В. Коваленко Breakdown of academic impact, for papers by Bruno Chiurazzi Breakdown of academic impact, for papers by Chu Van Nguyen Breakdown of academic impact, for papers by Petra Jankowska Breakdown of academic impact, for papers by Hanmei Lou Breakdown of academic impact, for papers by Carlijn van de Water
Rankless by CCL
2026